BERGEN, Norway, Jan. 21, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), announces that the first patient has been dosed in a phase I clinical trial evaluating the safety, tolerability, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback